MARKET

SCPS

SCPS

Scopus Biopharma Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4200
-0.0102
-2.37%
Closed 18:53 08/09 EDT
OPEN
0.4302
PREV CLOSE
0.4302
HIGH
0.4400
LOW
0.4200
VOLUME
31.69K
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
0.3411
MARKET CAP
8.86M
P/E (TTM)
-0.2617
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 07/26 12:14
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Benzinga · 06/21 08:44
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Benzinga · 06/13 08:28
44 Stocks Moving In Friday's Mid-Day Session
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Benzinga · 06/10 16:07
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 84 companies set new 52-week lows.
Benzinga · 06/09 17:21
BRIEF-Scopus Biopharma Received Deficiency Letter From Nasdaq
reuters.com · 05/27 22:16
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 05/18 12:17
BRIEF-Scopus BioPharma Inc- On April 4, Received Deficiency Notification Letter From Nasdaq Indicating Co Was Not In Compliance With Nasdaq Listing Rule
reuters.com · 04/08 21:21
More
No Data
Learn about the latest financial forecast of SCPS. Analyze the recent business situations of Scopus Biopharma Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SCPS stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
High12.00
Average12.00
Low12.00
Current 0.4200
EPS
Actual
Estimate
-0.78-0.58-0.39-0.19
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 20
Institutional Holdings: 1.01M
% Owned: 4.79%
Shares Outstanding: 21.09M
TypeInstitutionsShares
Increased
8
267.35K
New
3
112.04K
Decreased
3
72.64K
Sold Out
4
2.18M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Chairman/Chief Executive Officer/Director
Joshua Lamstein
Vice Chairman/Treasurer/Secretary/Director
Robert Gibson
Corporate Executive
Alan Horsager
Corporate Executive
Aharon Schwartz
Director
Ira Greenspan
Independent Director
David Battleman
Independent Director
David Buckel
Independent Director
Raphael Hofstein
Independent Director
David Weild
No Data
No Data
About SCPS
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.

Webull offers kinds of Scopus Biopharma Inc stock information, including NASDAQ:SCPS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCPS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCPS stock methods without spending real money on the virtual paper trading platform.